TXG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

139.41M

-8.95%

143.60M

-5.31%

155.21M

-5.94%

Estimates Revision

The market is revising No Change the revenue expectations for 10x Genomics, Inc. (TXG) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 74.72%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+74.72%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast TXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

13.00

High

18.00

Current: 0.000

Low

9.00

Averages

13.00

High

18.00

TD Cowen

Dan Brennan

Hold

maintain

$15 -> $18

2026-01-07

New

Reason

TD Cowen

Dan Brennan

Price Target

$15 -> $18

2026-01-07

New

maintain

Hold

Reason

TD Cowen analyst Dan Brennan raised the firm's price target on 10x Genomics to $18 from $15 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.

Canaccord

Buy

maintain

$19 -> $20

2025-12-22

Reason

Canaccord

Price Target

$19 -> $20

2025-12-22

maintain

Buy

Reason

Canaccord raised the firm's price target on 10x Genomics to $20 from $19 and keeps a Buy rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026, albeit they do see some risk for 10x Genomics shares.

BofA

Michael Ryskin

Neutral

maintain

$15 -> $18

2025-12-15

Reason

BofA

Michael Ryskin

Price Target

$15 -> $18

2025-12-15

maintain

Neutral

Reason

BofA analyst Michael Ryskin raised the firm's price target on 10x Genomics to $18 from $15 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.

Barclays

NULL

Overweight

maintain

$17 -> $22

2025-12-15

Reason

Barclays

Price Target

$17 -> $22

2025-12-15

maintain

NULL

Overweight

Reason

Barclays raised the firm's price target on 10x Genomics to $22 from $17 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Citi

Buy -> Neutral

downgrade

$18

2025-12-11

Reason

Citi

Price Target

$18

2025-12-11

downgrade

Buy -> Neutral

Reason

Citi downgraded 10x Genomics to Neutral from Buy with an unchanged price target of $18. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi cites cautious customer spending in 10x's academic and government end markets, an uncertain biotech recovery timing, ramping competition, and a balanced risk/reward post the recent rally for the downgrade.

Piper Sandler

Neutral

maintain

$15 -> $19

2025-11-11

Reason

Piper Sandler

Price Target

$15 -> $19

2025-11-11

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on 10x Genomics to $19 from $15 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.

Valuation Metrics

The current forward P/E ratio for 10X Genomics Inc (TXG.O) is -9.54, compared to its 5-year average forward P/E of -101.81. For a more detailed relative valuation and DCF analysis to assess 10X Genomics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-101.81

Current PE

-9.54

Overvalued PE

42.92

Undervalued PE

-246.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-563.65

Current EV/EBITDA

-8.95

Overvalued EV/EBITDA

1281.57

Undervalued EV/EBITDA

-2408.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

13.20

Current PS

2.27

Overvalued PS

24.98

Undervalued PS

1.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TXG News & Events

Events Timeline

No data

News

1.0

2025-12-29PRnewswire

10x Genomics to Present at 44th J.P. Morgan Healthcare Conference

6.0

2025-12-22Benzinga

JP Morgan Cuts Paychex Price Target to $125 Amid Underweight Rating

5.0

2025-12-13Yahoo Finance

Shifts in the Narrative Surrounding 10x Genomics Due to Recent Institutional Purchases and Product Developments

People Also Watch

Frequently Asked Questions

What is 10X Genomics Inc (TXG) stock price today?

The current price of TXG is 20.46 USD — it has increased 6.07 % in the last trading day.

What is 10X Genomics Inc (TXG)'s business?

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

What is the price predicton of TXG Stock?

What is 10X Genomics Inc (TXG)'s revenue for the last quarter?

10X Genomics Inc revenue for the last quarter amounts to 154.88M USD, increased 9.84 % YoY.

What is 10X Genomics Inc (TXG)'s earnings per share (EPS) for the last quarter?

10X Genomics Inc. EPS for the last quarter amounts to -0.28 USD, decreased -44.00 % YoY.

What changes have occurred in the market's expectations for 10X Genomics Inc (TXG)'s fundamentals?

How many employees does 10X Genomics Inc (TXG). have?

10X Genomics Inc (TXG) has 1306 emplpoyees as of January 10 2026.

What is 10X Genomics Inc (TXG) market cap?

Today TXG has the market capitalization of 2.38B USD.